Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · MANGALAM DRUG & CHEM LTD · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
MANGALAM DRUG & CHEM LTD
NSE: MANGALAM · BSE: 532637
NSE: MANGALAM · BSE: 532637
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
MANGALAM DRUG & CHEM LTD
StateQ1 FY27 filed
Last close · 20 Sept 2026₹32.94
Market cap₹0.1k cr
TTM P/E · P/B · EV/EBITDA— · 0.51 · —
MANGALAM DRUG & CHEM LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY24–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 369 | 318 | 232 |
| EBITDA (ex other income) | 17 | 36 | (15) |
| margin % | 4.7 | 11.3 | (6.4) |
| Owners' profit | 0 | 0 | 0 |
| EPS, as reported (₹) | (5.73) | 4.25 | (28.05) |
| ROE % · ROCE % | (6.7) · 1.7 | 4.5 · 11.3 | (43.1) · (27.3) |
| Debt / equity (x) | 0.65 | 0.54 | 1.02 |
| Cash from operations | (11) | 43 | 4 |
| Capex | 0 | (20) | (12) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MANGALAM DRUG & CHEM LTD · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 80 | 89 | 73 | 57 | 107 | 58 | 67 | 57 |
| Profit before tax | 1 | 1 | 2 | (13) | (25) | (10) | (13) | (7) |
| Net profit | 3 | 1 | 0 | (14) | (21) | (10) | (13) | (8) |
| EPS (₹) | 1.70 | 0.81 | 0.04 | (8.72) | (13.36) | (6.21) | (8.48) | (4.83) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/B | 0.5 | 3.3 | 7 of 164 | 96% |
| ROCE | (41.0) | 10.8 | 174 of 183 | 5% |
| ROE | (43.1) | 10.4 | 168 of 171 | 2% |
| Debt / Equity | 1.0 | 0.1 | 160 of 171 | 7% |
| EBITDA margin | 1.8 | 17.5 | 151 of 165 | 9% |
| Revenue growth | (0.4) | 16.3 | 123 of 161 | 24% |
| Profit growth | 44.6 | 30.9 | 69 of 158 | 57% |
| Market cap | 52 | 770 | 149 of 184 | 19% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · MANGALAM DRUG & CHEM LTD · 22 September 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 15 Sept 2026 · Bank loan default disclosed: about Rs 15.57 crore overdue across two lenders | credit debt | critical | — | — |
| 15 Sept 2026 · Appointment of Mr. Prabhakar Raghunath Zavar as Independent Director for 5 years | management changes | medium | — | — |
| 15 Sept 2026 · Board appoints Prabhakar Zavar as Independent Director for 5 years | management changes | medium | — | — |
| 1 Sept 2026 · Mangalam Drugs announces 53rd AGM on September 23, 2026 via video conferencing | compliance | minimal | — | — |
| 31 Aug 2026 · 53rd AGM on Sept 23, 2026 via VC; annual report dispatched electronically | compliance | minimal | — | — |
| 31 Aug 2026 · Mangalam Drugs 53rd AGM on Sep 23, 2026; annual report and notice filed | board shareholder meetings | medium | — | — |
| 17 Aug 2026 · Default on bank loans exceeds 30 days across two lenders | credit debt | critical | — | — |
| 13 Aug 2026 · Newspaper publication of Q1 FY27 unaudited financial results | compliance | minimal | — | — |
| 12 Aug 2026 · Board approves Q1 FY27 results, appoints Statutory and Secretarial Auditors for 5 years | management changes | medium | — | — |
| 12 Aug 2026 · Q1 FY27 Results: Net Loss Narrows to Rs 7.55 Cr vs Rs 13.73 Cr YoY | results | high | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in